Clinical significance of a myeloperoxidase gene polymorphism and inducible nitric oxide synthase expression in cirrhotic patients with hepatopulmonary syndrome

Abstract

The clinical significance of a myeloperoxidase (MPO) gene polymorphism and inducible nitric oxide synthase (iNOS) expression in cirrhotic patients with hepatopulmonary syndrome (HPS) was explored. Enrolled subjects were divided into three groups according to their disease/health conditions: the HPS group (cirrhotic patients with HPS; n=63), the non-HPS group (cirrhotic patients without HPS; n=182), and the control group (healthy subjects without liver disease; n=35). The distribution of the MPO −463 G/A genotype and its relationship with iNOS expression in a typical cell block from ascitic fluid were detected by immunohistochemistry and polymerase chain reaction-restricted fragment length polymorphism analysis (PCR-RFLP). In the HPS group, the partial pressure of oxygen in blood and ascitic fluid was significantly decreased (8.95±1.58 kPa and 6.81±0.95 kPa, respectively; both P<0.01), while the partial pressure of carbon dioxide significantly increased (4.62±0.20 kPa and 5.92±0.45 kPa, respectively; P<0.01). MPO and iNOS levels were significantly increased in the HPS group as compared with the non-HPS group. These increases were even more remarkable in ascitic fluid (41.36±11.62 and 13.23±4.81 μg/L; 10.27± 3.20 and 4.95±1.12 μg/L) than in blood (16.66±5.24 and 4.87±1.73 μg/L; 5.79±2.31 and 2.35±0.84 μg/L). The distribution of the MPO genotypes GG, GA, and AA were 76.2%, 22.2% and 1.6% in the HPS group, and 57.7%, 37.9% and 4.4% in the non-HPS group (P<0.05). The expression of iNOS was significantly higher in patients with the G alleles (G/G and G/A) (61.54%, 48/78) than in patients with A alleles (G/A and A/A) (38.46%, 30/78) (P<0.01). It was suggested that the expression levels of iNOS and MPO were correlated with HPS-induced hypoxemia. The MPO-463 G/A mutation might be a protective factor that prevents the development of HPS. The MPO might be involved in the regulation of iNOS expression. In humans, MPO pathways, the iNOS/NO system, and their interaction might have an impact on the occurrence and development of HPS.

Keywords

hepatopulmonary syndrome / myeloperoxidase / inducible nitric oxide synthase / polymorphism

References

[1] SchenkP., FuhrmanV., MadlC., et al.. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut, 2002, 51(6): 853-859

[2] AllerR., MoreiraV., BoixedaD., et al.. Diagnosis of hepatopulmonary syndrome with contrast transthoracic echocardiography and histological confirmation. Liver, 1998, 18(5): 285-287

[3] KikuchiH., OhkohchiN., OriiT., et al.. Living-related liver transplantation in patients with hepatopulmonary syndrome disease. Transplant Proc, 2000, 32(7): 2177-2178

[4] FallonM.B.. Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome. J Clin Gastroenterol, 2005, 39(Suppl): S138-S142

[5] ZhangX.J., KatsutaY., AkimotoT., et al.. Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligation. J Hepatol, 2003, 39(5): 724-730

[6] ZhuY.Y., JingB.W., LouY.H.. Experimental study of early lung injury caused by abdominal infection in rats. Zhongguo Jijiu Yixue Zazhi (Chinese), 2000, 20(3): 131-133

[7] MossmanB.T., ChurgA.. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med, 1998, 157(5): 1666-1680

[8] YanL.. Expression of nitric oxide synthase in human phagocytes up-regulates the production of TNF2α. Xibao Yu Fenzi Mianyixue Zazhi (Chinese), 1997, 13(1): 9-12

[9] YeR.G., LuZ.Y.. . Medicine (Chinese), 20046th ed.Beijing, People’s Medical Publishing House, 440-449

[10] Rodriguez-RoisinR., KrowkaM.J.. Hepatopulmonary syndrome—a liver-induced lung vascular disorder. N Engl J Med, 2008, 358(22): 2378-2387

[11] KlaesR., FriedrichT., SpitkovskyD., et al.. Overexpression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer, 2001, 92(2): 276-284

[12] KrowkaM.J., CorteseD.A.. Hepatopulmonary syndrome: current concepts in diagnostic and therapeutic considerations. Chest, 1994, 105(5): 1528-1537

[13] NarumiyaS., IshizakiT., WatanabeN.. Rho effectors and reorganization of actin cytoskeleton. FEBS Lett, 1997, 410(1): 68-72

[14] FanningA.S., MiticL.L., AndersonJ.M.. Transmembrane proteins in the tight junction barrier. J Am Soc Nephrol, 1999, 10(6): 1337-1345

[15] BrainJ.D., MolinaR.M., DeCampM.M., et al.. Pulmonary intravascular macrophages: their contribution to the mononuclear phagocyte system in 13 species. Am J Physiol, 1999, 276(1): L146-154

[16] ColganS.P., DzusA.L., ParkosC.A.. Epithelial exposure to hypoxia modulates neutrophil transepithelial migration. J Exp Med, 1996, 184(3): 1003-1015

[17] LiX., HanD.W., ZhaoL.F.. Effect of glycine on the expression of peroxisome proliferators-activated receptorα in the rat nonalchoholic fatty liver. Zhongguo Bingli Shengli Zazhi (Chinese), 2006, 22(9): 1829-1832

[18] BaileyM.T., EnglerH., SheridanJ.F.. Stress induces the translocation of cutaneous and gastrointestinal microflora to secondary lymphoid organs of C57BL/6 mice. J Neuroimmunol, 2006, 171(1–2): 29-37

[19] CutrnJ.C., PerrelliM.G., CanvalieriB., et al.. Microvascular dysfunction induced by reperfusion injury and protective effect of ischemic preconditioning. Free Radical Bio & Med, 2002, 33(9): 1200-1208

[20] FondevilaC., BusuttilR.W., Kupiec-WeglinskiJ.W.. Hepatic ischemia/reperfusion injury — a fresh look. EXP Mol Pathol, 2003, 74(2): 86-93

[21] ZhangC., ReiterC., EiseriehJ.P., et al.. L-Arginine chlorination products inhibit endothelial nitric oxide production. J Biol Chem, 2001, 276(29): 27 159-27 165

[22] AuchereF., Capeillere-BlandinC.. NADPH as a co-substrate for studies of the chlorinating activity of myeloperoxidase. Biochem J, 1999, 343(pt3): 603-613

[23] SchroederR.A., EwingC.A., SitamannJ.V., et al.. Pulmonary expression of iNOS and HO-1 protein is upregulated in a rat model of prehepatic portal hypertension. Dig Dis Sci, 2000, 45(12): 2405-2410

[24] RollaG., BrussinoL., ColagrandeP., et al.. Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med, 1998, 129(5): 375-378

[25] ZhangX.J., KatsutaY., AkimotoT., et al.. Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligation. J Hepatol, 2003, 39(5): 724-730

[26] HalpernM.D., HolubecH., DominguezJ.A., et al.. Hepatic inflammatory mediators contribute to intestinal damage in necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol, 2003, 284(4): 695-702

[27] AlizadehA.H., FatemiS.R., MirzaeeV., et al.. Clinical features of hepatopulmonary syndrome in cirrhotic patients. World J Gastroenterol, 2006, 12(12): 1954-1956

[28] KrowkaM.S., WisemanG.A., BurnettO.L., et al.. Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO₂ response to 100% oxygen, and brain uptake after ⁹⁹mTcMAA lung scanning. Chest, 2000, 118(3): 615-624

[29] AustinG.E., LamL., ZakiS.R., et al.. Sequence comparison of putative regulatory DNA of the 5′ flanking region of the myeloperoxidase gene in normal and leukemic bone marrow cells. Leukemia, 1993, 7(9): 1445-1450

[30] PiedrafitaF.J., MolanderR.B., VansantG., et al.. An Alu element in the myeloperoxidase promoter contains a composite SP 1-thyroid hormone-retinoic acid response element. J Biol Chem, 1996, 271(24): 14 412-14 420

[31] EiserichJ.P., BaldusS., BronnanM.L., et al.. Myeloporoxidase, a leukocyte-derived vascular NO oxidase. Science, 2002, 296(5577): 2391-2394

[32] Abu-SoudH.M., KhassawnehM.Y., SohnJ.T., et al.. Peroxidases inhibits nitric oxide (NO) dependent bronchodilation: development of a model describing NO-peroxidase interactions. Biochemistry, 2001, 40(39): 11 866-11 875

[33] ZhangC., PatelR., EiserichJ.P., et al.. Endothelial dysfunction is induced by proinflammatory oxidant hypochlorous acid. Am J Physiol Heart Circ Physiol, 2001, 281(4): H1469-H1475

[34] MaH., ZhaoX., WangY.Y., et al.. Research on hypoxia-inducible factor-1α and inducible nitric oxide synthase levels and portal hemodynamics in patients with hepatopulmonary syndrome. Zhongguo Jiceng Yiyao Zazhi (Chinese), 2010, 2(17): 145-148